VanEck Biotech ETF BBH

Morningstar Medalist Rating

Morningstar’s Analysis BBH

Will BBH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

VanEck Biotech ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings BBH

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings73.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

16.9890M
Healthcare

Gilead Sciences Inc

14.5477M
Healthcare

Vertex Pharmaceuticals Inc

8.2944M
Healthcare

Regeneron Pharmaceuticals Inc

8.0142M
Healthcare

Moderna Inc

6.6535M
Healthcare

argenx SE ADR

4.4724M
Healthcare

IQVIA Holdings Inc

4.3223M
Healthcare

Natera Inc

3.3818M
Healthcare

Revolution Medicines Inc Ordinary Shares

3.3718M
Healthcare

BeOne Medicines Ltd ADR

3.0416M
Healthcare

Sponsor Center